TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19000553

Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg, 8 mg, or 12 mg sustained-release tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg in fed state
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fesoterodine at all doses
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fesoterodine in PMs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fesoterodine
Number of subjects: 24
Study: 16308008

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen, 2.4 atmospheres absolute
Number of subjects: 64

Group type: COMPARATOR
Intervention: Atmospheric air, 1.5 atmospheres absolute
Number of subjects: 64
Study: 12617335

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 9

Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 9
Study: 10554126

Group type: EXPERIMENTAL
Intervention: Mineral supplementation (calcium and phosphorus) with vitamin D (500 IU/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mineral supplementation (calcium and phosphorus) with vitamin D (1000 IU/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Unsupplemented breast milk
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 70
Study: 8707495

Group type: EXPERIMENTAL
Intervention: Component approaches, checklist, and scale assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 1856145

Group type: EXPERIMENTAL
Intervention: Single dose of amikacin (15 mg/kg) given iv over 30 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dose of tobramycin (4.5 mg/kg) given iv over 30 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24‐h continuous infusion of amikacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24‐h continuous infusion of tobramycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two injections of amikacin (7.5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three injections of tobramycin (1.5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single injection of amikacin
Number of subjects: 0
Study: 6343143

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cimetidine and chlorpheniramine in combination
Number of subjects: 52
Study: 30468136

Group type: EXPERIMENTAL
Intervention: Mindfulness group therapy (MGT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (mostly cognitive-behavioral therapy)
Number of subjects: 0
Study: 30670359

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) at individualized targets (either caudate or nucleus accumbens) for 3 months
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 7
Study: 28767146

Group type: EXPERIMENTAL
Intervention: Red wine (RW) 375 ml/d for 4 weeks
Number of subjects: 22
Study: 25602465

Group type: EXPERIMENTAL
Intervention: S‐CBT (standard cognitive‐behavioral treatment)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: A‐CBT (culturally accommodated cognitive‐behavioral treatment)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cultural moderators (ethnic identity, familism)
Number of subjects: 70
Study: 24471459

Group type: EXPERIMENTAL
Intervention: Minoxidil 2% lotion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20934835

Group type: EXPERIMENTAL
Intervention: Bupropion SR + Contingency Management (CM)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo + Non-Contingency Management (non-CM)
Number of subjects: 134
Study: 19581463

Group type: EXPERIMENTAL
Intervention: Meropenem 10 mg/kg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Meropenem 20 mg/kg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Meropenem 40 mg/kg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 8-hour dosing interval
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 12-hour dosing interval
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 0.5-hour infusion time
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 4-hour infusion time
Number of subjects: 38
Study: 16735935

Group type: EXPERIMENTAL
Intervention: Testosterone 300 microg/day
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 15031238

Group type: EXPERIMENTAL
Intervention: Falls risk alert card with information brochure, exercise programme, education programme, and hip protectors
Number of subjects: 626

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 626
Study: 11432692

Group type: COMPARATOR
Intervention: Buspirone
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nefazodone
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 9446373

Group type: EXPERIMENTAL
Intervention: Percutaneous transjugular intrahepatic porto‐systemic shunt (TIPS)
Number of subjects: 20
Study: 8174828

Group type: EXPERIMENTAL
Intervention: Active cold pressor test (4 degrees C)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Adrenergic blockers (propranolol and phentolamine)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control cold pressor test (37 degrees C)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Stressful stimuli or adrenergic blockers
Number of subjects: 7
Study: 3146403

Group type: EXPERIMENTAL
Intervention: Cholecystectomy after positive CCK test
Number of subjects: 174

Group type: COMPARATOR
Intervention: Cholecystectomy for uncomplicated calculous gallbladder disease
Number of subjects: 174
Study: 30739288

Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3 and home exercise (HE)
Number of subjects: 173

Group type: COMPARATOR
Intervention: 800 IU vitamin D3 and no HE (Control)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D3 and HE
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3 and no HE
Number of subjects: 173
Study: 28323893

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (3 weekly sessions of 35 minutes moderate intensity walking/running followed by 25 minutes strength training)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 91
Study: 26152322

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 10 mg/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 30 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrocortisone therapies (10 mg/d and 30 mg/d)
Number of subjects: 30
Study: 23274785

Group type: EXPERIMENTAL
Intervention: PEG‐IFN monotherapy
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: PEG‐IFN±lamivudine
Number of subjects: 214
Study: 21649862

Group type: EXPERIMENTAL
Intervention: Exercise only
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Exercise plus DASH diet
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 52
Study: 18308788

Group type: EXPERIMENTAL
Intervention: Methylphenidate (mean dose: 14.7 mg; range: 10-30 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16834582

Group type: EXPERIMENTAL
Intervention: Benson Relaxation Technique (BRT) combined with medication
Number of subjects: 50

Group type: COMPARATOR
Intervention: Only medication (control group)
Number of subjects: 50
Study: 15042104

Group type: EXPERIMENTAL
Intervention: [(11)C]WAY‐100635 in recovered depressed subjects
Number of subjects: 32

Group type: COMPARATOR
Intervention: [(11)C]WAY‐100635 in healthy controls
Number of subjects: 32
Study: 11709742

Group type: EXPERIMENTAL
Intervention: Dose-dense ADoc regimen (4 cycles of Doxorubicin 50 mg/m², Docetaxel 75 mg/m² i.v. day 1, q day 15 or 22; G-CSF day 3-15 only for the dose-dense schedule)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: ADoc + Tamoxifen
Number of subjects: 292

Group type: COMPARATOR
Intervention: ADoc
Number of subjects: 292
Study: 9821453

Group type: EXPERIMENTAL
Intervention: High serum lithium levels (0.8‐1.0 mmol L‐1)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Low serum lithium levels (0.5‐0.8 mmol L‐1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Lithium treatment (both high and low levels)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High serum lithium levels
Number of subjects: 91

Group type: COMPARATOR
Intervention: Low serum lithium levels
Number of subjects: 91
Study: 7815279

Group type: EXPERIMENTAL
Intervention: Intranasal insulin formulation (delivered volumes of 80-160 microL)
Number of subjects: 12
Study: 2679333

Group type: EXPERIMENTAL
Intervention: Peroperative digital manipulation before removal
Number of subjects: 17

Group type: COMPARATOR
Intervention: Atraumatic removal
Number of subjects: 17
Study: 16335673

Group type: COMPARATOR
Intervention: Adrenocortical carcinoma
Number of subjects: 27

Group type: COMPARATOR
Intervention: Adrenocortical adenoma
Number of subjects: 27

Group type: COMPARATOR
Intervention: Adrenal metastases
Number of subjects: 27
Study: 31026353

Group type: EXPERIMENTAL
Intervention: Counterweight-Plus weight management programme
Number of subjects: 1000
Study: 25724407

Group type: EXPERIMENTAL
Intervention: Oral palonosetron (0.50 mg) with oral dexamethasone
Number of subjects: 738

Group type: COMPARATOR
Intervention: IV palonosetron (0.25 mg) with oral dexamethasone
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Oral palonosetron (0.50 mg)
Number of subjects: 738

Group type: COMPARATOR
Intervention: IV palonosetron (0.25 mg)
Number of subjects: 738
Study: 23453674

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hydrocortisone + Phenytoin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 22020357

Group type: COMPARATOR
Intervention: Placebo + fluoxetine (≤80 mg/d of fluoxetine)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Clomipramine + fluoxetine (≤75 and ≤40 mg/d, respectively)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Quetiapine + fluoxetine (≤200 and ≤40 mg/d, respectively)
Number of subjects: 54
Study: 19635614

Group type: EXPERIMENTAL
Intervention: BZA 20 mg with CE 0.625 mg
Number of subjects: 3397

Group type: EXPERIMENTAL
Intervention: BZA 40 mg with CE 0.45 mg
Number of subjects: 3397

Group type: EXPERIMENTAL
Intervention: BZA 10 mg with CE 0.625 mg
Number of subjects: 3397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3397
Study: 16757491

Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK) and usual care
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK) and mandatory invasive study < or = 24 h
Number of subjects: 304

Group type: COMPARATOR
Intervention: Primary PCI with 300 mg loading dose of clopidogrel
Number of subjects: 304
Study: 15300231

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CS) 3 mg/kg/day intravenously, with subsequent oral dosing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cyclosporine (CS) plus Methotrexate (MTX) 15 mg/m2 on day 1, and 10 mg/m2 on days 3, 6, and 11
Number of subjects: 80
Study: 11760331

Group type: EXPERIMENTAL
Intervention: Independent study method of physical assessment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional lecture method of instruction
Number of subjects: 20
Study: 9480608

Group type: EXPERIMENTAL
Intervention: Eve 20 (20 micrograms ethinylestradiol EE, 500 micrograms norethisterone)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Lovelle (20 micrograms ethinylestradiol EE, 150 micrograms Desogestrel)
Number of subjects: 118
Study: 8138651

Group type: EXPERIMENTAL
Intervention: Intramuscular buprenorphine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intramuscular pentazocine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intramuscular nefopam
Number of subjects: 75
Study: 3313041

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily)
Number of subjects: 4081

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4081

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 4081
Study: 29545639

Group type: EXPERIMENTAL
Intervention: EEG analysis in DLB patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG analysis in DLB and PDD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dementia groups (DLB, AD, PDD)
Number of subjects: 0
Study: 30931750

Group type: EXPERIMENTAL
Intervention: DI‐15 High‐Fidelity Electronic Earplugs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Music PRO Electronic Earplugs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Other hearing protection devices (HPDs)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electronic HPDs
Number of subjects: 15
Study: 23897052

Group type: EXPERIMENTAL
Intervention: Oxiplex gel (carboxymethylcellulose/polyethylene oxide gel) applied during surgery
Number of subjects: 68

Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 68
Study: 23102853

Group type: EXPERIMENTAL
Intervention: Enhanced invitation letter
Number of subjects: 800

Group type: COMPARATOR
Intervention: Standard invitation letter (control group)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Age group at diagnosis
Number of subjects: 800
Study: 21122466

Group type: EXPERIMENTAL
Intervention: Carbachol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PACAP38
Number of subjects: 0

Group type: COMPARATOR
Intervention: VIP
Number of subjects: 0
Study: 18206149

Group type: EXPERIMENTAL
Intervention: Auditory stress condition
Number of subjects: 56

Group type: COMPARATOR
Intervention: Auditory control condition
Number of subjects: 56
Study: 16831781

Group type: EXPERIMENTAL
Intervention: Single session group intervention
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard care control condition
Number of subjects: 26
Study: 12897592

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10900154

Group type: EXPERIMENTAL
Intervention: Methotrexate (5 mg/m(2)/week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No immunosuppressive treatment (Control)
Number of subjects: 10
Study: 8970308

Group type: EXPERIMENTAL
Intervention: Revised curriculum intervention
Number of subjects: 38
Study: 1474534

Group type: EXPERIMENTAL
Intervention: Nabumetone (2000 mg/day)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Naproxen (1000 mg/day)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 298

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 298
Study: 6386412

Group type: EXPERIMENTAL
Intervention: Test meals with added fat (potatoes, rice, apples)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Test meals without added fat (potatoes, rice, apples)
Number of subjects: 14
Study: 31544569

Group type: EXPERIMENTAL
Intervention: Uncorrected ametropia (myopia)
Number of subjects: 24296

Group type: COMPARATOR
Intervention: Gender
Number of subjects: 24296

Group type: COMPARATOR
Intervention: Age
Number of subjects: 24296

Group type: COMPARATOR
Intervention: Ethnicity
Number of subjects: 24296
Study: 29973132

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27265390

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 1114
Study: 24811969

Group type: EXPERIMENTAL
Intervention: Four-factor PCC (Beriplex P/N)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Three-factor PCC (Profilnine SD)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 35
Study: 22218138

Group type: EXPERIMENTAL
Intervention: Radial nerve mobilization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (intermittent ultrasound therapy)
Number of subjects: 60
Study: 20185423

Group type: EXPERIMENTAL
Intervention: PCT-guided antimicrobial treatment
Number of subjects: 550

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: PCT-guided treatment (advised)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: PCT-guided treatment (overruled)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 550
Study: 17852871

Group type: EXPERIMENTAL
Intervention: Multiprofessional education programme
Number of subjects: 93

Group type: COMPARATOR
Intervention: Regular information (Control)
Number of subjects: 93
Study: 16213926

Group type: EXPERIMENTAL
Intervention: Short-term immunotherapy (STI) with molecular standardized allergens (ALK(7), n = 24) plus anti-allergic drugs
Number of subjects: 48

Group type: COMPARATOR
Intervention: Anti-allergic drugs alone (n = 24)
Number of subjects: 48
Study: 12145716

Group type: EXPERIMENTAL
Intervention: Amphotericin B colloidal dispersion (ABCD; 6 mg/kg/day)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Amphotericin B (AmB; 1.0-1.5 mg/kg/day)
Number of subjects: 174
Study: 11409825

Group type: EXPERIMENTAL
Intervention: Hinged ankle‐foot orthosis (HAFO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Posterior leaf spring (PLS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Solid ankle‐foot orthosis (SAFO)
Number of subjects: 30
Study: 9037575

Group type: EXPERIMENTAL
Intervention: Levodopa (LD) plus bromocriptine (Br)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Levodopa (LD) alone
Number of subjects: 50
Study: 8379178

Group type: EXPERIMENTAL
Intervention: Retrograde Venous Perfusion (RVP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Systemic intravenous infusions (SVI)
Number of subjects: 20
Study: 3510660

Group type: EXPERIMENTAL
Intervention: Ketoconazole, 200 mg twice daily for male partners
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo for male partners
Number of subjects: 117
Study: 29168473

Group type: EXPERIMENTAL
Intervention: Yangxin Tongmai Formula (YTF) administered orally for 60 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Yangxin Tongmai Formula (YTF)
Number of subjects: 40
Study: 27031726

Group type: EXPERIMENTAL
Intervention: Bilateral tDCS over the temporal-parietal region with right anode/left cathode configuration
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bilateral tDCS over the temporal-parietal region with right cathode/left anode configuration
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 13
Study: 25912854

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics (clindamycin or first-generation cephalosporin) for 2 to 4 days followed by oral antibiotics for 20 to 30 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics (clindamycin or first-generation cephalosporin)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Open incisional trepanation (trephination)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bone biopsy for bacteriology
Number of subjects: 14
Study: 23090007

Group type: EXPERIMENTAL
Intervention: No-overlap condition (high fluency salience)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Overlap condition (low fluency salience)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study: 20698383

Group type: EXPERIMENTAL
Intervention: Proctored simulator training (human expert feedback plus simulator feedback)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Independent simulator training (automated simulator feedback only)
Number of subjects: 13
Study: 18215665

Group type: EXPERIMENTAL
Intervention: 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 3.6 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 96
Study: 16770746

Group type: EXPERIMENTAL
Intervention: SIPA (integrated service model)
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1230
Study: 14725657

Group type: EXPERIMENTAL
Intervention: Sclerosing foam (polidocanol 3% solution, 2.0 or 2.5 mL injection)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sclerosing liquid (polidocanol 3% solution, 2.0 or 2.5 mL injection)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sclerosing liquid
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sclerosing foam
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sclerosing foam and liquid
Number of subjects: 88
Study: 16464192

Group type: EXPERIMENTAL
Intervention: Data collection strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combining different collection methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proxies to collect resource utilization estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient self-reported data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Method of collecting data
Number of subjects: 0
Study: 8838703

Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 1594260

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 10
Study: 30071830

Group type: EXPERIMENTAL
Intervention: Sports Stars intervention (eight, one-hour, weekly physiotherapy group sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study: 26443600

Group type: EXPERIMENTAL
Intervention: Air-balloon technique (AB)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Gel-filling technique (GF)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 26
Study: 24845165

Group type: EXPERIMENTAL
Intervention: Buprenorphine taper (4-week duration)
Number of subjects: 10
Study: 23758302

Group type: EXPERIMENTAL
Intervention: Computer-based intervention (CBI)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Therapist and computer-based intervention (T+CBI)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control group (resource brochure only)
Number of subjects: 397
Study: 21169166

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (n = 88)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Internet-based problem-solving therapy (n = 88)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Waiting list (n = 87)
Number of subjects: 263